Geneseeq

Founded in 2013, Geneseeq Technology Inc. is a global leader in next-generation sequencing (NGS)-based precision cancer care, offering comprehensive solutions for cancer detection, diagnosis, and treatment across all stages of cancer. Geneseeq’s product portfolio spans from multi-cancer early detection (MCED) for healthy individuals that appear to be healthy, to MRD monitoring for early stage cancer, and comprehensive genomic profiling as well as cancer-specific panel for advanced cancer.

Multi-Cancer Early Detection (MCED)

Our CanScan product combines whole genome sequencing (WGS) with fragmentomics technology, enabling highly sensitive early detection of multiple cancers in asymptomatic individuals. In 2023, CanScan received FDA Breakthrough Device Designation, recognizing its innovative approach to early-stage cancer screening.

Early MRD Monitoring

For the early stage cancer, MRD surveillance becomes essential in evaluating treatment efficacy and detecting minimal residual disease (MRD), which may indicate the risk of relapse. Geneseeq’s MRD assays offer high-sensitivity detection of low-frequency mutations, helping clinicians track residual tumor presence dynamically at multiple critical time points, ensuring timely intervention and optimal care.

Comprehensive Genomic Profiling for Advanced Cancer

For patients with advanced cancers, Geneseeq offers comprehensive genomic profiling panels for both solid tumor and blood cancer, delivering detailed molecular insights into tumor DNA. This profiling identifies key biomarkers such as TMB, MSI, and dMMR, which are essential for guiding personalized treatment decisions.

Currently, we offer a range of CE-marked, FDA-approved, and NMPA-certified CDx kits for asymptomatic individuals, early and advanced cancer stage patients. In August 2025, GENESEEQPRIME, our comprehensive pan-cancer genomic profiling product, received FDA approval. Additionally, GENESEEQPRIME, along with the ESSENCARE lung cancer panel, has already obtained NMPA certification.

Specific Cancer Panels for Targeted Therapies

Geneseeq also offers specific cancer panels tailored to commonly encountered cancer types including breast cancer, sarcomas, lung cancer, gynecologic cancer, gastrointestinal, CNS cancer, urologic and blood cancer etc.

Integrated Testing and Data Analysis

Geneseeq’s oncology solutions are integrated into the GENESIS platform, a powerful bioinformatics tool that automatically do the data analysis and generates standardized clinical reports. The platform ensures rapid turnaround times and provides clinicians with actionable, real-time insights to support decision-making at every stage of cancer care.

Cancer, a word, not a sentence.

Geneseeq thrives to establish new benchmarks in healthcare innovation. We collaborate with clinicians, researchers, biopharmaceutical companies, government agencies, and regulatory bodies to consistently practice precision oncology and validate new technologies. Together, we stand in our commitment to empowering lives and reshaping the future of cancer care.

Certifications and Expertise

For Laboratory Services (Sample Testing):
Our clinical laboratories hold CAP, CLIA, ISO 15189 and CNAS ISO 15189 accreditations, ensuring that all testing services adhere to the highest national and international standards. These certifications demonstrate our commitment to delivering reliable, accurate, and globally compliant results.

For In-Vitro Diagnostic (IVD) Kits:
Geneseeq’s manufacturing facilities are certified under EN ISO 13485:2016 + A11:2021 and comply with the MDSAP (Medical Device Single Audit Program) framework, ensuring the quality, safety, and global regulatory compliance of our IVD products.